Marie-Pierre David

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M Wheeler, 2014, Clinical and Vaccine Immunology.

A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.

Marie-Pierre David, Luis Rivera, Crisanta Rocha, 2006, Revista panamericana de salud publica = Pan American journal of public health.

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.

Marie-Pierre David, Gary Dubin, P. van Damme, 2009, Gynecologic oncology.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Jack T Stapleton, Arunachalam Ilancheran, Frank Struyf, 2014, The Lancet.

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

Thomas Breuer, Marie-Pierre David, Gary Dubin, 2008, Vaccine.